Evidence map›Paper›PMID 37429736›Full record

ReviewPharmacological reviews2023

Optical Approaches for Investigating Neuromodulation and G Protein-Coupled Receptor Signaling.

David J Marcus, Michael R Bruchas

Open access · hybridAbstract readReview
In one paragraph

Review in Pharmacological reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Engineering signalling pathways in mammalian cells.Nature biomedical engineering · 2024
    Review
  8. Review
  9. Subcellular activation of β-adrenergic receptors using a spatially restricted antagonist.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

David J MarcusCenter for the Neurobiology of Addiction, Pain and Emotion (D.J.M., M.R.B.), Department of Anesthesiology and Pain Medicine (D.J.M., M.R.B.), Department of Pharmacology (M.R.B.), and Department of Bioengineering (M.R.B.), University of Washington, Seattle, Washington djmarcus@uw.edu mbruchas@uw.edu.
Michael R BruchasCenter for the Neurobiology of Addiction, Pain and Emotion (D.J.M., M.R.B.), Department of Anesthesiology and Pain Medicine (D.J.M., M.R.B.), Department of Pharmacology (M.R.B.), and Department of Bioengineering (M.R.B.), University of Washington, Seattle, Washington djmarcus@uw.edu mbruchas@uw.edu.
University of Washington · US

Funding

Project 4_Bruchas : Circuit-level Approaches for Dissecting Approach/Avoidance Behaviors Mediated by Nociceptin Systems in MiceP50MH119467 · NIMH · MCLEAN HOSPITAL · PI GRAYBIEL, ANN M · 2020 to 2024
$15.9M
Decoding Locus Coeruleus Neural Circuits and Signaling In Negative AffectR01MH112355 · NIMH · WASHINGTON UNIVERSITY · PI Michael R. Bruchas · 2016 to 2026
$5.3M
Next Generation Opto-GPCRs for Neuromodulatory ControlU01NS128537 · NINDS · UNIVERSITY OF WASHINGTON · PI Andre Berndt, Michael R. Bruchas · 2023 to 2026
$4.4M
DISSECTING DYNORPHIN-KAPPA OPIOID MEDIATED REINSTATEMENT OF NICOTINE PREFERENCER37DA033396 · NIDA · WASHINGTON UNIVERSITY · PI Michael R. Bruchas · 2018 to 2026
$3.8M
Next-gen Opto-GPCRs: spatiotemporal simulation of neuromodulator signalingR01MH111520 · NIMH · WASHINGTON UNIVERSITY · PI BRUCHAS, MICHAEL R., SUNAHARA, ROGER K · 2016 to 2018
$3.2M
Sleep, opiate withdrawal and the N/OFQ - NOP systemR01HL150836 · NHLBI · SRI INTERNATIONAL · PI BRUCHAS, MICHAEL R., KILDUFF, THOMAS S · 2019 to 2019
$2.0M
DISSECTING DYNORPHIN-KAPPA OPIOID MEDIATED REINSTATEMENT OF NICOTINE PREFERENCER01DA033396 · NIDA · WASHINGTON UNIVERSITY · PI BRUCHAS, MICHAEL R. · 2013 to 2017
$1.9M
Optopharmacology and Sensors for Dissecting Opioid Action In VivoR61DA051489 · NIDA · UNIVERSITY OF WASHINGTON · PI BRUCHAS, MICHAEL R., GU, LIANGCAI · 2020 to 2022
$1.2M
Neurotensinergic-eCB modulation of reward and aversion via a PVT-NAc circuitF32DA054709 · NIDA · UNIVERSITY OF WASHINGTON · PI MARCUS, DAVID J. · 2021 to 2023
$189k
NHLBI NIH HHS R01 HL150836NIDA NIH HHS F32 DA054709NIDA NIH HHS R01 DA033396NIDA NIH HHS R37 DA033396NIDA NIH HHS R61 DA051489NIMH NIH HHS P50 MH119467NIMH NIH HHS R01 MH111520NIMH NIH HHS R01 MH112355NINDS NIH HHS U01 NS128537
6 · The paper itself

Abstract

Despite the fact that roughly 40% of all US Food and Drug Administration (FDA)-approved pharmacological therapeutics target G protein-coupled receptors (GPCRs), there remains a gap in our understanding of the physiologic and functional role of these receptors at the systems level. Although heterologous expression systems and in vitro assays have revealed a tremendous amount about GPCR signaling cascades, how these cascades interact across cell types, tissues, and organ systems remains obscure. Classic behavioral pharmacology experiments lack both the temporal and spatial resolution to resolve these long-standing issues. Over the past half century, there has been a concerted effort toward the development of optical tools for understanding GPCR signaling. From initial ligand uncaging approaches to more recent development of optogenetic techniques, these strategies have allowed researchers to probe longstanding questions in GPCR pharmacology both in vivo and in vitro. These tools have been employed across biologic systems and have allowed for interrogation of everything from specific intramolecular events to pharmacology at the systems level in a spatiotemporally specific manner. In this review, we present a historical perspective on the motivation behind and development of a variety of optical toolkits that have been generated to probe GPCR signaling. Here we highlight how these tools have been used in vivo to uncover the functional role of distinct populations of GPCRs and their signaling cascades at a systems level. SIGNIFICANCE STATEMENT: G protein-coupled receptors (GPCRs) remain one of the most targeted classes of proteins for pharmaceutical intervention, yet we still have a limited understanding of how their unique signaling cascades effect physiology and behavior at the systems level. In this review, we discuss a vast array of optical techniques that have been devised to probe GPCR signaling both in vitro and in vivo.

Indexed as

Receptors, G-Protein-CoupledSignal TransductionHumansLigandsOptogeneticsPharmaceutical PreparationsLigandsPharmaceutical PreparationsReceptors, G-Protein-Coupled

Identifiers

PMID37429736
PMCPMC10595021
OpenAlexW4383872814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.